These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2540215)

  • 1. Aldose reductase in the etiology of diabetic complications: I. Introduction.
    Harrison HE; Stribling D; Armstrong FM; Perkins CM
    J Diabet Complications; 1989; 3(1):6-11. PubMed ID: 2540215
    [No Abstract]   [Full Text] [Related]  

  • 2. The identification of aldose reductase in the pathogenesis of diabetic complications: the background.
    Kador PF; Kinoshita JH
    Diabet Med; 1985 May; 2(3):187-9. PubMed ID: 2952417
    [No Abstract]   [Full Text] [Related]  

  • 3. Aldose reductase in diabetic cataracts.
    Kinoshita JH; Kador P; Catiles M
    JAMA; 1981 Jul; 246(3):257-61. PubMed ID: 6787220
    [No Abstract]   [Full Text] [Related]  

  • 4. Aldose reductase in the etiology of diabetic complications: 2. Nephropathy.
    Stribling D; Armstrong FM; Harrison HE
    J Diabet Complications; 1989; 3(2):70-6. PubMed ID: 2526143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of aldose reductase by nonenzymatic glycosylation.
    Srivastava SK; Ansari NH; Bhatnagar A; Hair G; Liu S; Das B
    Prog Clin Biol Res; 1989; 304():171-84. PubMed ID: 2506561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldose reductase inhibitors and diabetic complications.
    Raskin P; Rosenstock J
    Am J Med; 1987 Aug; 83(2):298-306. PubMed ID: 3113248
    [No Abstract]   [Full Text] [Related]  

  • 7. Aldose reductase inhibition, glomerular metabolism, and diabetic nephropathy.
    Cohen M
    Diabet Med; 1985 May; 2(3):203-6. PubMed ID: 3032499
    [No Abstract]   [Full Text] [Related]  

  • 8. Aldose reductase in the diabetic eye. XLIII Edward Jackson memorial lecture.
    Kinoshita JH
    Am J Ophthalmol; 1986 Dec; 102(6):685-92. PubMed ID: 3098107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutathione redox state is not the link between polyol pathway activity and myo-inositol-related Na+-K+-ATPase defect in experimental diabetic neuropathy.
    Carroll PB; Thornton BM; Greene DA
    Diabetes; 1986 Nov; 35(11):1282-5. PubMed ID: 3019809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lens aldose reductase in diabetic and galactosemic cataracts.
    Parmar NS; Ghosh MN
    Indian J Physiol Pharmacol; 1981; 25(3):193-200. PubMed ID: 6795119
    [No Abstract]   [Full Text] [Related]  

  • 11. The involvement of aldose reductase in diabetic complications.
    Kinoshita JH; Nishimura C
    Diabetes Metab Rev; 1988 Jun; 4(4):323-37. PubMed ID: 3134179
    [No Abstract]   [Full Text] [Related]  

  • 12. Aldose reductase in the etiology of diabetic complications. 3. Neuropathy.
    Stribling D; Armstrong FM; Perkins CM; Smith JC
    J Diabet Complications; 1989; 3(3):139-48. PubMed ID: 2528557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical localization for aldose reductase in diabetic lenses.
    Akagi Y; Kador PF; Kinoshita JH
    Invest Ophthalmol Vis Sci; 1987 Jan; 28(1):163-7. PubMed ID: 3100473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symposium: Aldose reductase and the complications of diabetes mellitus: reviews of preclinical studies in eyes, nerves, and kidneys. London, September 1984. Proceedings.
    Diabet Med; 1985 May; 2(3):185-212. PubMed ID: 2952416
    [No Abstract]   [Full Text] [Related]  

  • 15. Recent advances in the therapy of diabetic peripheral neuropathy by means of an aldose reductase inhibitor.
    Greene DA; Lattimer SA
    Am J Med; 1985 Nov; 79(5A):13-7. PubMed ID: 3000175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased myo-inositol content and Na+-K+-ATPase activity in superior cervical ganglion of STZ-diabetic rat and prevention by aldose reductase inhibition.
    Greene DA; Mackway AM
    Diabetes; 1986 Oct; 35(10):1106-8. PubMed ID: 3019804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldose reductase inhibitors: an approach to the treatment of diabetic nerve damage.
    Greene DA; Sima AA; Stevens MJ; Feldman EL; Killen PD; Henry DN; Thomas T; Dananberg J; Lattimer SA
    Diabetes Metab Rev; 1993 Oct; 9(3):189-217. PubMed ID: 8187607
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical application of aldose reductase inhibitors--prevention and therapy of diabetic complications].
    Hotta N; Sakamoto N
    Nihon Rinsho; 1987 Dec; 45(12):3010-27. PubMed ID: 3128677
    [No Abstract]   [Full Text] [Related]  

  • 19. The pharmacology of aldose reductase inhibitors.
    Kador PF; Robison WG; Kinoshita JH
    Annu Rev Pharmacol Toxicol; 1985; 25():691-714. PubMed ID: 3923907
    [No Abstract]   [Full Text] [Related]  

  • 20. The dog as a model for ocular manifestations of high concentrations of blood sugars.
    Wyman M; Sato S; Akagi Y; Terubayashi H; Datiles M; Kador PF
    J Am Vet Med Assoc; 1988 Nov; 193(9):1153-6. PubMed ID: 3143694
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.